The Journal of Urology
Volume 180, Issue 4 , Pages 1303-1308 , October 2008

Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3

  • Donna Pauler Ankerst

      Affiliations

    • Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas
    • Department of Epidemiology and Biostatistics, University of Texas Health Sciences Center, San Antonio, Texas
    • Corresponding Author InformationCorrespondence: Department of Urology, UTHSCSA, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229 (telephone: 210-567-5643; FAX: 210-567-6868)
    • ,
  • Jack Groskopf

      Affiliations

    • Gen-Probe, Incorporated, San Diego, California
    • Financial interest and/or other relationship with Gen-Probe Inc.
    • ,
  • John R. Day

      Affiliations

    • Gen-Probe, Incorporated, San Diego, California
    • Financial interest and/or other relationship with Gen-Probe Inc.
    • ,
  • Amy Blase

      Affiliations

    • Gen-Probe, Incorporated, San Diego, California
    • Financial interest and/or other relationship with Gen-Probe Inc.
    • ,
  • Harry Rittenhouse

      Affiliations

    • Gen-Probe, Incorporated, San Diego, California
    • Financial interest and/or other relationship with Gen-Probe Inc.
    • ,
  • Brad H. Pollock

      Affiliations

    • Department of Epidemiology and Biostatistics, University of Texas Health Sciences Center, San Antonio, Texas
    • ,
  • Cathy Tangen

      Affiliations

    • Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Dipen Parekh

      Affiliations

    • Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas
    • ,
  • Robin J. Leach

      Affiliations

    • Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas
    • Department of Cellular and Structural Biology, University of Texas Health Sciences Center, San Antonio, Texas
    • ,
  • Ian Thompson

      Affiliations

    • Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas

Received 13 February 2008

References 

  1. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95:1276
  2. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215
  3. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004;350:2239
  4. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA. 2005;294:66
  5. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529
  6. Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T, et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology. 2006;68:1152
  7. Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007;25:3076
  8. Hernandez DJ, Han M, Humphreys EB, Mangold LA, Brawer MK, Taneja SS, et al. External validation of the prostate cancer risk calculator. J Urol, suppl. 2007;177:622;abstract 1874.
  9. Han M, Humphreys EB, Hernandez DJ, Partin AW, Roehl KA, Catalona WJ. Comparison between the prostate cancer risk calculator and serum PSA. J Urol, suppl. 2007;177:622;abstract 1875
  10. Reed A, Ankerst DP, Pollock BH, Thompson IM, Parekh DJ. Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. J Urol. 2007;178:1929
  11. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695
  12. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007;69:532
  13. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587
  14. Schervish MJ. Theory of Statistics. New York: Springer-Verlag Inc; 1995;403
  15. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837
  16. Chun FK, Briganti A, Graefen M, Porter C, Montorsi F, Haese A, et al. Development and external validation of an extended repeat biopsy nomogram. J Urol. 2007;177:510
  17. Porter CR, Gamito EJ, Crawford ED, Bartsch G, Presti JC, Tewari A, et al. Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting. Urology. 2005;65:937
  18. Finne P, Finne R, Bangma C, Hugosson J, Hakama M, Auvinen A, et al. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer. 2004;111:310
  19. Wang TJ, Gona P, Larson MG, Levy D, Benjamin EJ, Tofler GH, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631
  20. Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98:1204

 Supported by the Early Detection Research Network, National Cancer Institute, National Institutes of Health Grant U01-CA86402 and the San Antonio Cancer Institute Grant P30-CA54174.

 For another article on a related topic see page 1515.

PII: S0022-5347(08)01570-X

doi: 10.1016/j.juro.2008.06.038

The Journal of Urology
Volume 180, Issue 4 , Pages 1303-1308 , October 2008

Article Tools

* Image Usage & Resolution